Cytokinetics (NASDAQ: CYTK) EVP exercises options, sells 15,000 shares at $85.80

Q: What was the sale price for the CYTK shares sold by Andrew Callos?

The 15,000 shares of Cytokinetics common stock sold by Andrew Callos were transacted at an average price of $85.80 per share. The filing characterizes this transaction as an open-market or private sale under transaction code S .

Q: At what price did Andrew Callos exercise his Cytokinetics stock options?

Andrew Callos exercised options to acquire 15,000 shares of Cytokinetics common stock at an exercise price of $23.26 per share. The transaction is coded M , indicating an exercise or conversion of a derivative security into common stock.

Q: What Cytokinetics stock options does Andrew Callos retain after this Form 4?

After these transactions, Andrew Callos holds 24,000 non-qualified stock options with an exercise price of $23.26 per share, expiring on March 31, 2031 . These options vest over four years, with a one-year cliff then monthly vesting, contingent on continued employment.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

CYTOKINETICS INC executive Andrew Callos reported an option exercise paired with a sale of common stock. On July 1, 2026, he exercised options to acquire 15,000 shares of Common Stock at $23.26 per share, then sold 15,000 shares in an open-market transaction at an average price of $85.80 per share. Following these transactions, he directly owns 58,555 shares of Common Stock and holds 24,000 non-qualified stock options with a $23.26 exercise price expiring on March 31, 2031. The stock options referenced vest over four years, with an initial one-year cliff and monthly vesting thereafter, subject to continued employment.

Insider Trade Summary 10b5-1

Net Seller: 15,000 shares ($1,287,000)

Net Sell 3 txns

Insider Callos Andrew

Role EVP, Chief Commercial Officer

Sold 15,000 shs ($1.29M)

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (Right to Buy)	15,000	$0.00	--
Exercise	Common Stock	15,000	$23.26	$349K
Sale	Common Stock	15,000	$85.80	$1.29M

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 24,000 shares (Direct, null); Common Stock — 73,555 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares sold: 15,000 shares Sale price: $85.80/share Options exercised: 15,000 shares +4 more

7 metrics

Shares sold 15,000 shares Open-market sale of Common Stock at $85.80 on July 1, 2026

Sale price $85.80/share Average price for 15,000 Common Stock shares sold

Options exercised 15,000 shares Common Stock acquired via option exercise coded M

Exercise price $23.26/share Exercise price of Non-Qualified Stock Option

Shares held after 58,555 shares Direct Common Stock ownership following transactions

Remaining options 24,000 options Non-Qualified Stock Options expiring March 31, 2031

Option expiration date March 31, 2031 Expiration of Non-Qualified Stock Option (Right to Buy)

Key Terms

Non-Qualified Stock Option (Right to Buy), open-market sale, derivative exercise/conversion, exercise or conversion of derivative security, +1 more

5 terms

Non-Qualified Stock Option (Right to Buy) financial

"security_title: "Non-Qualified Stock Option (Right to Buy)""

open-market sale financial

"transaction_action: "open-market sale" for Common Stock transaction"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative exercise/conversion financial

"transaction_action: "derivative exercise/conversion" with code M"

exercise or conversion of derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

vesting financial

"footnote: "Stock options will vest over 4 years from the date of the grant""

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 05:19 PM Accepted by SEC EDGAR 07/02/2026 - 05:19 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Callos Andrew

(Last)

(First)

(Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/01/2026		M		15,000	A	$23.26	73,555	D
Common Stock	07/01/2026		S		15,000	D	$85.8	58,555	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Qualified Stock Option (Right to Buy)	$23.26	07/01/2026		M			15,000	03/31/2022⁽¹⁾	03/31/2031	Common Stock	15,000	$0	24,000	D

Explanation of Responses:

1. Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer.

	/s/ John O. Faurescu, attorney-in-fact for Mr. Callos	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did CYTK EVP Andrew Callos report on this Form 4?

Andrew Callos reported an option exercise and matching share sale. He exercised options for 15,000 shares of Cytokinetics common stock at $23.26, then sold 15,000 shares in an open-market transaction at $85.80 per share on July 1, 2026.

How many CYTK shares does Andrew Callos hold after the reported transactions?

After the reported transactions, Andrew Callos directly holds 58,555 shares of Cytokinetics common stock. This figure reflects his position following the exercise of 15,000 options and the sale of 15,000 shares on July 1, 2026.

What was the sale price for the CYTK shares sold by Andrew Callos?

The 15,000 shares of Cytokinetics common stock sold by Andrew Callos were transacted at an average price of $85.80 per share. The filing characterizes this transaction as an open-market or private sale under transaction code S.

At what price did Andrew Callos exercise his Cytokinetics stock options?

Andrew Callos exercised options to acquire 15,000 shares of Cytokinetics common stock at an exercise price of $23.26 per share. The transaction is coded M, indicating an exercise or conversion of a derivative security into common stock.

What Cytokinetics stock options does Andrew Callos retain after this Form 4?

After these transactions, Andrew Callos holds 24,000 non-qualified stock options with an exercise price of $23.26 per share, expiring on March 31, 2031. These options vest over four years, with a one-year cliff then monthly vesting, contingent on continued employment.

What is Andrew Callos’s role at Cytokinetics (CYTK) mentioned in this Form 4?

The Form 4 identifies Andrew Callos as an officer of Cytokinetics, serving as EVP, Chief Commercial Officer. The reported transactions therefore reflect activity by a senior executive with direct ownership of company common stock and non-qualified stock options.